and/or pegylated liposomal doxorubicin in 7 patients. Another 9 patients received the liposomal drug alone. Plasma elimination of the pegylated liposomal agent followed a biexponential curve withmedian t1/2α and t1/2β of 2 and 45 hours, respectively. The drug detected in the plasma was exclusively in the liposomal form, confirming the stability of this agent in vivo. Both the plasma clearance (...

BACKGROUND Pegylated liposomal doxorubicin (PLD), a formulation with pharmacokinetic differences with respect to doxorubicin (DXR), might benefit patients with advanced soft tissue sarcoma (STS) pretreated with DXR. PATIENTS AND METHODS Patients with measurable and progressive STS received PLD at 35 mg/(2) every 3 weeks. Quality of life before and during treatment was assessed with EORTC QLQ-...

The confluence of nanotechnology and biotechnology provides significant commercial opportunities. By identifying, classifying and tracking firms with capabilities in both biotechnology and nanotechnology over time, we analyze the emergence and evolution of the global nanobiotechnology industry. Research in nanotechnology has expanded rapidly in the last 15 years, but the development of commerci...

The nanostructured drugs for cancer treatment that have so far reached the oncology market largely rely on passive targeting (p.e.: Abraxane, Doxil, Daunoxome, Oncaspar, DepoCyt), meaning that they are not empowered by specific mechanisms to recognize specific cell types or tissues. Preferential but still passive accumulation into tumor tissues is thus favored; in addition the increase in circu...

The therapeutic efficacy of systemic drug delivery vehicles is limited by their ability to evade the mononuclear phagocyte system, preferentially localize to the target tissue, and negotiate past the endothelial barrier. In order to create a delivery vehicle capable of all these functions, we developed a biomimetic functionalization of synthetic particles using membranes isolated from leukocyte...

653. Spencer, A., Prince, H.M., Roberts, A.W., Prosser,I.W., Bradstock, K.F., Coyle, L., Gill, D.S.,Horvath, N., Reynolds, J. & Kennedy, N. (2009)Consolidation therapy with low-dose thalido-mide and prednisolone prolongs the survival of multiple myeloma patients undergoing a singleautologous stem-cell transplantation procedure. Journal of Clinical Oncology, 27, 1788–1793. Sr...

This issue of the Journal of Controlled Release (JCR) presents 12 articles, and all of them deal with nanomedicine. It is time to reflect on the workdone the last fewdecades onnanomedicine, inparticular, in relation to drug delivery. It has not beenuncommon to havemost of the articles in each issue of JCR deal with various forms of nanoparticles for drug delivery. Having such a large number of ...

Therapeutic DeliveryVol. 12, No. 4 EditorialDrug repurposing supported by nanotechnology: a promising strategy to fight cancerMohammad NajlahMohammad Najlah *Author for correspondence: E-mail Address: [email protected]://orcid.org/0000-0001-7670-2859Pharmaceutical Research Group, School of Allied Health, Faculty Education, Medicine & Social Care, Anglia Ruskin University, Bishops H...

We read with interest the paper by Dimopoulos et al. concerning a comparison of bortezomib plus dexamethasone (BzD) versus bortezomib monotherapy in relapsed multiple myeloma (MM). In their manuscript the authors presented a post hocmatched-pair analysis of patients treated in three separate clinical studies: MMY-2045 (patients treated with BzD), APEX (patients treated with singleagent bortezom...

The goal of initial treatment for transplant eligible patients with multiple myeloma (MM) is to achieve the deepest possible response in an effort to attain prolonged event-free survival after transplant. There has been an excellent response to the threedrug regimens of agents approved for upfront use (Table 1), including bortezomib/IMiD (thalidomide or lenalidomide) dexamethasone (VTD or VRD) ...